Loading skill
Install any skill in seconds. Free to start, no credit card required.
Get Started Free →asgard-ai-platform/tw-healthcare-regulations
Navigate Taiwan healthcare regulations including NHI system, medical device classification, drug registration, telemedicine rules, and health data protection.
Passed 19 of 22 test cases with the skill, and 17 of 22 without it.
2 fixed17 passed either way3 still failing0 broke
Tokens, turns and time describe resource use, not a dollar price.
One of 2 test cases the skill fixed. Same model, same prompt, with and without the skill.
We are expanding our digital health mobile app into Taiwan to enable remote follow-up visits and continuous blood pressure monitoring for chronic disease management. Please prepare a formal regulatory evaluation following the Healthcare Regulatory Assessment structure: provide the product classification (type, risk category, regulatory body), a regulatory pathway table with procedural steps, timelines, and costs, an NHI monetization strategy, and an actionable compliance checklist.
| Checked | Without skill | With skill |
|---|---|---|
| Cites the Regulations Governing Telemedicine Diagnosis and Treatment for remote chronic disease follow-up. | Passed | Passed |
| Restricts remote consultation scope to follow-up visits rather than initial patient consultations. | Missed | Passed |
| Evaluates data privacy requirements under Taiwan's Personal Data Protection Act (PDPA). | Passed | Passed |
The instructions your model reads when the skill loads.
IRON LAW: NHI Shapes Everything in Taiwan Healthcare
Taiwan's National Health Insurance (全民健保) covers 99.9% of the
population. Any healthcare product or service strategy in Taiwan must
account for NHI — either by getting NHI reimbursement (volume play)
or by positioning as self-pay/premium (margin play).
Ignoring NHI is like ignoring gravity.
| Aspect | Detail |
|---|---|
| Coverage | 99.9% of population (23M+ people) |
| Single payer | 衛生福利部中央健康保險署 (NHIA) |
| Premium | 5.17% of insured salary (shared: employer 60%, employee 30%, government 10%) |
| Co-pay | Outpatient: NT$50-420. Hospitalization: 5-30% (capped) |
| Drug pricing | NHIA sets reimbursement prices via Drug Expenditure Target (DET) |
| Annual budget | ~NT$800B+ (growing 4-5% annually) |
| Class | Risk | Examples | Approval Path | Timeline |
|---|---|---|---|---|
| Class I | Low | Bandages, tongue depressors | Registration (listing) | 1-2 months |
| Class II | Medium | Blood pressure monitors, surgical gloves | Technical review | 6-12 months |
| Class III | High | Implants, AI diagnostic software | Full clinical review | 12-24 months |
| SaMD (Software as Medical Device) | Varies by intended use | AI diagnosis, clinical decision support | Class II or III depending on risk | 6-24 months |
Regulatory body: 衛生福利部食品藥物管理署 (TFDA)
| Category | Regulation Status | Key Rule |
test cases passed, vs 17 / 22 without
More skills from the same source and nearby in the registry, with their headline benchmark lift.